Bradley McGregor, MD, Dana-Farber Cancer Institute

Articles

PD-1 Vs PD-L1 Inhibition for Frontline mRCC

May 12th 2021

A panel of oncologists discuss the appropriateness for using PD-1 inhibitors versus PD-L1 inhibitors as frontline treatment for metastatic renal cell carcinoma.

The CLEAR Study in mRCC

May 12th 2021

Robert S. Alter, MD, of the John Theurer Cancer Center, highlights key data revealed by the phase 3 CLEAR study in metastatic renal cell carcinoma.

Frontline Treatment for mRCC: Dose Adjustments/Discontinuation

May 5th 2021

Advice for appropriately dosing newer novel-based strategies used to treat metastatic renal cell carcinoma and best practices to help community oncologists avoid drug discontinuations.

Frontline Therapy for mRCC: Assessing Quality of Life

May 5th 2021

Expert oncologists debate the significance of using quality of life as a metric when assessing patients’ responses to therapy for metastatic renal cell carcinoma.

The CheckMate 9ER Study in mRCC

April 28th 2021

Takeaways of the CheckMate 9ER trial of nivolumab plus cabozantinib vs sunitinib in previously untreated metastatic renal cell carcinoma.

Novel Strategies for Intermediate-/Poor-Risk mRCC: Optimizing Therapy

April 28th 2021

Drs Bradley A. McGregor and David F. McDermott comment on best approaches for selecting and optimizing treatment with novel combination regimens to manage patients with intermediate- or poor-risk metastatic renal cell carcinoma.

Lenvatinib-Based Combinations for Intermediate-/Poor-Risk mRCC

April 21st 2021

Thomas E. Hutson, DO, PharmD, of Texas Oncology, reacts to results demonstrated by the CLEAR study of lenvatinib in combination with pembrolizumab or everolimus for the treatment of metastatic renal cell carcinoma and discusses best practices for educating community oncologists on dosing with lenvatinib.

Frontline Treatment for Intermediate/Poor-Risk mRCC

April 21st 2021

Considerations for evolving from using single-agent therapy to combination approaches to treat intermediate or poor-risk metastatic renal cell carcinoma based on more recent data demonstrated in clinical trials.

Favorable-Risk mRCC: Aggressive Therapy and Disease Progression

April 14th 2021

The rationale for treating favorable-risk metastatic renal cell carcinoma with early, aggressive therapy and considerations for approaching disease progression.

Favorable-Risk mRCC: First-Line Treatment Selection

April 14th 2021

Oncologists discuss how they select an appropriate novel combination strategy as first-line therapy for patients with favorable-risk metastatic renal cell carcinoma.